Zobrazeno 1 - 10
of 247
pro vyhledávání: '"Geir E. Tjønnfjord"'
Publikováno v:
Journal of Medical Case Reports, Vol 18, Iss 1, Pp 1-7 (2024)
Abstract Background Natalizumab is a monoclonal antibody used to treat patients with relapsing–remitting multiple sclerosis. Anemia is a recognized side effect, but it is usually mild and of a short duration when natalizumab is stopped. Here, we de
Externí odkaz:
https://doaj.org/article/fc2cecd946034d73a262b7b311f3683b
Autor:
Christian Qvigstad, Lars Q. Sørensen, Geir E. Tjønnfjord, Pål André Holme, Ingrid Pabinger, Cedric Hermans, Roseline d’Oiron, Robert Klamroth, Johannes Oldenburg, Natascha Marquardt, Peter Staritz, Olga Katsarou, Uri Martinowitz, Aharon Lubetsky, Gili Kenet, Annarita Tagliaferri, Maria Elisa Mancuso, Roger Schutgens, Pål André HolmE, Jerzy Windyga, Irena Zupan, Victor Jimenez Yuste, Ramiro Nunez, Philippe de Moerloose, Erik Berntorp, Jan Astermark, Campbell Tait, Gerry Dolan
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 8, Iss 5, Pp 102514- (2024)
Background: People with hemophilia often experience pain and suffer from comorbidities related to their bleeding disorder. Consequently, unemployment due to disability is prevalent among people with hemophilia. Objectives: To explore associations bet
Externí odkaz:
https://doaj.org/article/bbbcde5173814e1f8d9095c20136a013
Autor:
Ina Kreyberg, MD, PhD, Elisabeth Schrumpf, MD, PhD, Carl Fredrik von Krogh, MD, Rune Lilleng, MD, Geir E. Tjønnfjord, MD, PhD
Publikováno v:
JAAD Case Reports, Vol 41, Iss , Pp 33-36 (2023)
Externí odkaz:
https://doaj.org/article/ad1350d7f308460c992df7ad2539ef97
Autor:
Johanne U. Hermansen, Yanping Yin, Aleksandra Urban, Camilla V. Myklebust, Linda Karlsen, Katrine Melvold, Anders A. Tveita, Kjetil Taskén, Ludvig A. Munthe, Geir E. Tjønnfjord, Sigrid S. Skånland
Publikováno v:
Cell Death Discovery, Vol 9, Iss 1, Pp 1-10 (2023)
Abstract The microenvironment of chronic lymphocytic leukemia (CLL) cells in lymph nodes, spleen, and bone marrow provides survival, proliferation, and drug resistance signals. Therapies need to be effective in these compartments, and pre-clinical mo
Externí odkaz:
https://doaj.org/article/c9d49e1d86744257bcc85e229f404a21
Autor:
Aleksandra Urban, Johanne Hermansen, Yanping Yin, Weikaixin Kong, Rebecca Teglgaard, Christian Brieghel, Sabina Kersting, Geir E. Tjønnfjord, Mark-David Levin, Hoa T. T. Tran, Mattias Mattsson, Juha Ranti, Gerrit-Jan Veldhuis, Caspar Da Cunha-Bang, Rogier Mous, Julie Dubois, Arnon Kater, Carsten Niemann, Tero Aittokallio, Sigrid Skånland
Publikováno v:
HemaSphere, Vol 7, p e92046ec (2023)
Externí odkaz:
https://doaj.org/article/69ae2e40c7fe4a2ca9baae0e3b9e3035
Autor:
Leonardo Miranda Santana, Deepak B. Thimiri Govinda Raj, Andrea Cremaschi, Mariaserena Giliberto, Alexandra Gade, Arnoldo Frigessi, Geir E. Tjønnfjord, Ludvig A. Munthe, Sigrid S. Skånland, Manuela Zucknick, Kjetil Taskén
Publikováno v:
HemaSphere, Vol 7, p e743599b (2023)
Externí odkaz:
https://doaj.org/article/fd7ad490e30e42b99eeb8b1340c8b413
Autor:
Sigrid S. Skånland, Geir E. Tjønnfjord
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 8, Pp 1-7 (2022)
Abstract Targeted therapies against phosphatidylinositol 3-kinase (PI3K), Bruton’s tyrosine kinase (BTK), and B-cell lymphoma-2 (BCL-2) are approved for chronic lymphocytic leukemia (CLL). Since approval of the first-in-class drugs, next-generation
Externí odkaz:
https://doaj.org/article/9b49410398f8460089f156da1c1d247e
Autor:
Åslaug Helland, Hege G. Russnes, Gro Live Fagereng, Khalid Al-Shibli, Yvonne Andersson, Thomas Berg, Line Bjørge, Egil Blix, Bodil Bjerkehagen, Sigmund Brabrand, Marte Grønlie Cameron, Astrid Dalhaug, Dalia Dietzel, Tom Dønnem, Espen Enerly, Åsmund Flobak, Sverre Fluge, Bjørnar Gilje, Bjørn Tore Gjertsen, Bjørn Henning Grønberg, Kari Grønås, Tormod Guren, Hanne Hamre, Åse Haug, Daniel Heinrich, Geir Olav Hjortland, Eivind Hovig, Randi Hovland, Ann-Charlotte Iversen, Emiel Janssen, Jon Amund Kyte, Hedda von der Lippe Gythfeldt, Ragnhild Lothe, Jo-Åsmund Lund, Leonardo Meza-Zepeda, Monica Cheng Munthe-Kaas, Olav Toai Duc Nguyen, Pitt Niehusmann, Hilde Katarina NilsenPuco, Anne Hansen Ree, Tonje Bøyum Riste, Karin Semb, Eli Sihn Samdal Steinskog, Andreas Stensvold, Pål Suhrke, Øyvind Tennøe, Geir E. Tjønnfjord, Liv Jorunn Vassbotn, Eline Aas, Kristine Aasebø, Kjetil Tasken, Sigbjørn Smeland
Publikováno v:
Journal of Translational Medicine, Vol 20, Iss 1, Pp 1-11 (2022)
Abstract Background Matching treatment based on tumour molecular characteristics has revolutionized the treatment of some cancers and has given hope to many patients. Although personalized cancer care is an old concept, renewed attention has arisen d
Externí odkaz:
https://doaj.org/article/bc8aeb65ca3b4815a6a4cb94d009f0a6
Autor:
Katrine Melvold, Mariaserena Giliberto, Linda Karlsen, Pilar Ayuda‐Durán, Robert Hanes, Toril Holien, Jorrit Enserink, Jennifer R. Brown, Geir E. Tjønnfjord, Kjetil Taskén, Sigrid S. Skånland
Publikováno v:
Molecular Oncology, Vol 16, Iss 5, Pp 1153-1170 (2022)
Most patients with chronic lymphocytic leukemia (CLL) initially respond to targeted therapies, but eventually relapse and develop resistance. Novel treatment strategies are therefore needed to improve patient outcomes. Here, we performed direct drug
Externí odkaz:
https://doaj.org/article/67352beffad14b0ba011733748ab3689
Autor:
Mariaserena Giliberto, Deepak B. Thimiri Govinda Raj, Andrea Cremaschi, Sigrid S. Skånland, Alexandra Gade, Geir E. Tjønnfjord, Fredrik Schjesvold, Ludvig A. Munthe, Kjetil Taskén
Publikováno v:
Molecular Oncology, Vol 16, Iss 6, Pp 1241-1258 (2022)
The management of multiple myeloma (MM) is challenging: An assortment of available drug combinations adds complexity to treatment selection, and treatment resistance frequently develops. Given the heterogeneous nature of MM, personalized testing tool
Externí odkaz:
https://doaj.org/article/71633b5db14044a08b75a456ac66df48